
Breakthroughs that
See news releases about Etira, our stellar team,


Research on Etira drugs win awards at AACR 2025
NewsChicago, IL – April 30, 2025:Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.Adriana Baker, who presented…

Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
NewsChicago, IL - April 23, 2025:
Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as…

Second site activated for ERX-315 trial
NewsAdelaide, Australia – March 17, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research…

ERX-315 Phase 1 Clinical Trial Update
NewsSydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase…

Dr. Raj appointed as Etira Chief Medical Officer
NewsDallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…
Where to find us
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247